William Blair raised the price target for the Cullinan Therapeutics Inc (NASDAQ:CGEM) stock to “an Outperform”. The rating was released on April 15, 2024, according to finviz. The stock was initiated by BTIG Research, who disclosed in a research note on November 21, 2022, to Buy and set the price objective to $20. In their research brief published April 27, 2021, Morgan Stanley analysts upgraded the Cullinan Therapeutics Inc stock from Equal-Weight to Overweight with a price target of $40.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 61.56% within the last five trades and 42.70% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 196.95% in the last 6 months and 93.57% was added to its value over the previous 3 months. CGEM stock is trading at a margin of 47.26%, 47.14% and 108.99% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of the close of trading, CGEM deals in the Healthcare domain. The stock is trading 22.70 percent below its 52-week high and 231.15 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 82.22. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Cullinan Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $1.09 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 2.39, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 38.83 percent of Cullinan Therapeutics Inc shares are owned by insiders, and 56.13 percent are held by financial institutions. Savill Corrine, the Chief Business Officer at Cullinan Therapeutics Inc (CGEM) has sold 40,000 shares of firm on Feb 01 ’24 at a price of $16.18 against the total amount of $0.65 million. In another inside trade, Savill Corrine, Chief Business Officer of Cullinan Therapeutics Inc (NASDAQ:CGEM) sold 40,000 shares of the firm on Jan 29 ’24 for a total worth of $0.56 million at a price of $14.09. An inside trade which took place on Jan 23 ’24, Chief Business Officer of Cullinan Therapeutics Inc Savill Corrine sold 21,316 shares of firm against total price of $0.27 million at the cost of $12.46 per share.
